Ovarian Cancer With Malignant Ascites
Conditions
Brief summary
To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer. To analyze the clinical significance of the concentration change of vascular endothelial growth factor (VEGF) in ascites in treatment of intraperitoneal injection bevacizumab
Interventions
DRUGBevacizumab
DRUGTC:paclitaxel + carboplatin
Sponsors
Chinese PLA General Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Inclusion criteria
* Signed informed consent obtained prior to initiation of any study-specific procedures and treatment as confirmation of the patient's awareness and willingness to comply with the study requirements. * Histologically confirmed and documented ovarian cancer with malignant ascites. * ECOG(Eastern Cooperative Oncology Group, ECOG) PS 0-2. * Life expectancy of \>3 months. * No serious inadequate bone marrow function, liver and renal function or significant cardiovascular disease.
Exclusion criteria
* Known hypersensitivity to any of the study drugs or excipients. * Any current anti-cancer therapy. * No evidence of ascites. * Key organ dysfunction. * Significant cardiovascular disease (e.g. congestive heart failure (CHF), uncontrolled cardiac arrhythmia, angina, heart valve disease, myocardial infarction and refractory hypertension need to be long time controlled by medicine). * Non-healing wound, ulcer or bone fracture. * Uncontrolled psychiatric history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate | 24month |
Countries
China
Contacts
Primary ContactNan Du, PhD
Backup ContactJihua Chen, MD
Outcome results
None listed